Skip to main content

SARS-CoV-2 Infection

47
Pipeline Programs
30
Companies
50
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
1
6
10
19
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
350%
Vaccine
233%
Small Molecule
117%
+ 59 programs with unclassified modality

On Market (3)

Approved therapies currently available

GENOSYLApproved
nitric oxide
Unknown Company
Vasodilator [EPC]inhalation2019
ULSPIRAApproved
nitric oxide
Unknown Company
Vasodilator [EPC]inhalation2023
INOMAXApproved
nitric oxide
Unknown Company
Vasodilator [EPC]inhalation1999

Competitive Landscape

33 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
11 programs
1
1
4
4
1
BNT162b2Phase 4
BNT162b2Phase 3
BNT162b2Phase 3
BNT162b2Phase 3
BNT162b2Phase 3
+6 more programs
Active Trials
NCT05799495Completed240Est. Oct 2023
NCT05403307Completed757Est. Jul 2023
BioNTech
BioNTechCA - San Diego
11 programs
1
1
4
4
1
BNT162b2Phase 41 trial
BNT162b2Phase 31 trial
BNT162b2Phase 31 trial
BNT162b2Phase 31 trial
BNT162b2Phase 31 trial
+6 more programs
Active Trials
NCT05541861Completed383Est. Nov 2024
NCT05004181Completed1,380Est. Oct 2023
NCT04368728Completed46,969Est. Feb 2023
+8 more trials
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
3 programs
1
1
Moderna COVID-19 VaccinePhase 3Vaccine3 trials
B/HPIV3/S-6PPhase 11 trial
S-217622PHASE_31 trial
Active Trials
NCT05305547Completed2,093Est. May 2024
NCT06026514Completed27Est. Jun 2025
NCT05077254Completed48Est. Feb 2025
+2 more trials
Novavax
NovavaxMD - Gaithersburg
3 programs
2
1
SARS-CoV-2 rS/Matrix M1-AdjuvantPhase 31 trial
NVX-CoV2373Phase 21 trial
SARS-CoV-2 rS/Matrix-M1 AdjuvantPhase 21 trial
Active Trials
NCT05112848Completed384Est. Nov 2022
NCT04533399Completed4,422Est. Jan 2022
NCT04583995Completed15,185Est. Mar 2022
Innovation Pharmaceuticals
2 programs
2
FavipiravirPhase 3Small Molecule1 trial
Remdesivir-HUPhase 31 trial
Active Trials
NCT04600999Completed14Est. Dec 2020
NCT04610541Unknown2,000Est. Nov 2021
SaNOtize
SaNOtizeBC - Vancouver
2 programs
2
Nitric OxidePhase 31 trial
Nitric OxidePhase 31 trial
Active Trials
NCT05109611Terminated1,389Est. Apr 2024
NCT05599919Completed306Est. Feb 2022
Shionogi
ShionogiJapan - Osaka
2 programs
2
S-217622Phase 3
S-217622Phase 31 trial
Active Trials
NCT05897541Completed2,387Est. Sep 2024
Nanogen Pharmaceutical Biotechnology
Nanogen Pharmaceutical BiotechnologyVietnam - Ho Chi Minh City
1 program
1
NanocovaxPhase 31 trial
Active Trials
NCT04922788Completed13,006Est. Jul 2022
Bayer
BayerLEVERKUSEN, Germany
1 program
1
SARS-CoV-2 mRNA VaccinePhase 3RNA Therapeutic1 trial
Active Trials
NCT04848467Withdrawn0Est. Nov 2022
Verity Pharmaceuticals
1 program
1
VPM1002Phase 31 trial
Active Trials
NCT04439045Completed122Est. Sep 2021
Valneva
ValnevaAustria - Vienna
2 programs
2
VLA2001Phase 2/31 trial
VLA2001Phase 2/31 trial
Active Trials
NCT05298644Withdrawn0Est. Aug 2025
NCT05364242Completed178Est. May 2023
Beech Tree Labs
1
BTL-TML-COVIDPhase 21 trial
Active Trials
NCT04522830Completed28Est. Feb 2021
Rhizen Pharmaceuticals
1
RP7214 + Standard of carePhase 21 trial
Active Trials
NCT05007236Completed163Est. Mar 2022
NGM Biopharmaceuticals
1 program
1
NGM621Phase 1/21 trial
Active Trials
NCT04582318Terminated16Est. Mar 2021
Bio-Thera Solutions
Bio-Thera SolutionsChina - Guangzhou
1 program
1
BAT2022Phase 1
Biocorp
BiocorpFrance - Issoire
1 program
1
BAT2022Phase 11 trial
Active Trials
NCT05518695Completed32Est. Nov 2022
Emergent BioSolutions
1
COVID-HIGPhase 11 trial
Active Trials
NCT05142306Completed23Est. May 2022
Celltrion
CelltrionKorea - Incheon
4 programs
CT-P59PHASE_11 trial
CT-P59PHASE_11 trial
CT-P63PHASE_11 trial
CT-P59PHASE_2_31 trial
Active Trials
NCT04525079Completed32Est. Nov 2020
NCT04593641Completed18Est. Apr 2021
NCT05017168Completed24Est. Jan 2022
+1 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
DZIF-10cPHASE_1_21 trial
DZIF-10cPHASE_1_21 trial
Active Trials
NCT04631666Completed57Est. Aug 2021
NCT04631705Terminated45Est. Sep 2021
Breathe BioMedical
Breathe BioMedicalMA - Cambridge
1 program
Breath Analysis of Patients Diagnosed With COVID-19 Using Infrared SpectroscopyN/A1 trial
Active Trials
NCT04867213Unknown200Est. Mar 2022
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)N/A1 trial
Active Trials
NCT05687877Completed366Est. Jan 2025
Alder Therapeutics
Alder TherapeuticsSweden - Solna
1 program
Innova Lateral Flow TestN/A1 trial
Active Trials
NCT05614427Completed449Est. Apr 2022
Frontera Therapeutics
Frontera TherapeuticsChina - Suzhou
1 program
Lockdown and other social distancing measuresN/A1 trial
Active Trials
NCT05069090Completed1,038Est. Apr 2021
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Sinopharm VaccineN/AVaccine1 trial
Active Trials
NCT05362682Unknown3,000Est. Aug 2024
Sona Nanotech
Sona NanotechNS - Halifax
1 program
Sona Saliva C-19 Rapid Self-testN/A1 trial
Active Trials
NCT05256589Completed500Est. May 2022
Thermo Fisher Scientific
1 program
The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select PanelN/A1 trial
Active Trials
NCT05727202Completed1,909Est. Apr 2024
MediaPharma
MediaPharmaItaly - Chieti
1 program
thoracic CT-scanN/A1 trial
Active Trials
NCT04534400Unknown1,000Est. Mar 2024
Memo Therapeutics
Memo TherapeuticsSwitzerland - Schlieren
1 program
MTx-COVAB36PHASE_11 trial
Active Trials
NCT05351437Completed32Est. Nov 2022
Bharat Serums & Vaccines
Equine COVID-19 AntiserumPHASE_1_21 trial
Active Trials
NCT04834908Terminated7Est. May 2022
Virogin Biotech
Virogin BiotechBC - Richmond
1 program
COVID-19 mRNA VaccinePHASE_2RNA Therapeutic1 trial
Active Trials
NCT06113731Unknown980Est. Oct 2024

+3 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BioNTechBNT162b2
ShionogiS-217622
Allergy TherapeuticsS-217622
BioNTechBNT162b2
SaNOtizeNitric Oxide
SaNOtizeNitric Oxide
BayerSARS-CoV-2 mRNA Vaccine
BioNTechBNT162b2
Nanogen Pharmaceutical BiotechnologyNanocovax
BioNTechBNT162b2
Allergy TherapeuticsModerna COVID-19 Vaccine
BioNTechBNT162b2
Innovation PharmaceuticalsRemdesivir-HU
Innovation PharmaceuticalsFavipiravir
NovavaxSARS-CoV-2 rS/Matrix M1-Adjuvant

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 124,866 patients across 50 trials

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults

Start: Oct 2020Est. completion: Nov 2021160 patients
Phase 4Completed

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

Start: Jun 2023Est. completion: Sep 20242,387 patients
Phase 3Completed

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

Start: Aug 2022Est. completion: May 20242,093 patients
Phase 3Completed

Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age

Start: Apr 2022Est. completion: Oct 20221,134 patients
Phase 3Completed

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection

Start: Nov 2021Est. completion: Apr 20241,389 patients
Phase 3Terminated

Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19

Start: Nov 2021Est. completion: Feb 2022306 patients
Phase 3Completed
NCT04848467BayerSARS-CoV-2 mRNA Vaccine

COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older

Start: Oct 2021Est. completion: Nov 20220
Phase 3Withdrawn

To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.

Start: Jul 2021Est. completion: May 202316,372 patients
Phase 3Completed

Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19

Start: Jun 2021Est. completion: Jul 202213,006 patients
Phase 3Completed

A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults

Start: Apr 2021Est. completion: Dec 2021629 patients
Phase 3Completed
NCT04811664Allergy TherapeuticsModerna COVID-19 Vaccine

A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

Start: Mar 2021Est. completion: Dec 20211,923 patients
Phase 3Completed

A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

Start: Feb 2021Est. completion: Jul 20211,574 patients
Phase 3Completed

REMdesivir-HU Clinical Study and Severe Covid-19 Patients

Start: Oct 2020Est. completion: Nov 20212,000 patients
Phase 3Unknown

Clinical Trial of Favipiravir Treatment of Patients With COVID-19

Start: Oct 2020Est. completion: Dec 202014 patients
Phase 3Completed
NCT04583995NovavaxSARS-CoV-2 rS/Matrix M1-Adjuvant

A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom

Start: Sep 2020Est. completion: Mar 202215,185 patients
Phase 3Completed

Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity

Start: Jun 2020Est. completion: Sep 2021122 patients
Phase 3Completed

A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

Start: Aug 2023Est. completion: Mar 20251,051 patients
Phase 2/3Completed

Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19

Start: Dec 2022Est. completion: Jul 20241,550 patients
Phase 2/3Unknown

COVID-19 Paediatric VLA2001-321 Study

Start: Oct 2022Est. completion: Aug 20250
Phase 2/3Withdrawn
NCT05472038BioNTechBNT162b5 Bivalent

A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals

Start: Jul 2022Est. completion: Mar 20241,453 patients
Phase 2/3Completed

VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection

Start: May 2022Est. completion: May 2023178 patients
Phase 2/3Completed

To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

Start: Feb 2021Est. completion: Jul 2022726 patients
Phase 2/3Completed

A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection

Start: Oct 2020Est. completion: Oct 20211,642 patients
Phase 2/3Completed

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

Start: Apr 2020Est. completion: Feb 202346,969 patients
Phase 2/3Completed
NCT06113731Virogin BiotechCOVID-19 mRNA Vaccine

A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

Start: Jul 2023Est. completion: Oct 2024980 patients
Phase 2Unknown

A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized

Start: May 2023Est. completion: Oct 2023240 patients
Phase 2Completed

A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)

Start: Feb 2022Est. completion: Nov 2022384 patients
Phase 2Completed
NCT05077254Allergy TherapeuticsModerna COVID-19 Vaccine

COVID Protection After Transplant-Immunosuppression Reduction

Start: Dec 2021Est. completion: Feb 202548 patients
Phase 2Completed
NCT05007236Rhizen PharmaceuticalsRP7214 + Standard of care

Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.

Start: Sep 2021Est. completion: Mar 2022163 patients
Phase 2Completed

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

Start: Aug 2021Est. completion: Oct 20231,380 patients
Phase 2Completed
NCT04761822Allergy TherapeuticsModerna COVID-19 Vaccine

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

Start: Apr 2021Est. completion: Apr 2022746 patients
Phase 2Completed
NCT04621123GrifolsConvalescent anti-SARS-CoV-2 MBT plasma

Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients

Start: Nov 2020Est. completion: Jul 2021384 patients
Phase 2Completed
NCT04533399NovavaxSARS-CoV-2 rS/Matrix-M1 Adjuvant

A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults

Start: Aug 2020Est. completion: Jan 20224,422 patients
Phase 2Completed

A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19

Start: Jul 2020Est. completion: Feb 202128 patients
Phase 2Completed
NCT04834908Bharat Serums & VaccinesEquine COVID-19 Antiserum

Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection

Start: Jul 2021Est. completion: May 20227 patients
Phase 1/2Terminated

SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation

Start: Dec 2020Est. completion: Sep 202145 patients
Phase 1/2Terminated

SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion

Start: Dec 2020Est. completion: Aug 202157 patients
Phase 1/2Completed

A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19

Start: Nov 2020Est. completion: Mar 202116 patients
Phase 1/2Terminated

Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults

Start: Sep 2023Est. completion: Jun 202527 patients
Phase 1Completed
NCT05541861BioNTechBNT162b2 Bivalent

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People

Start: Nov 2022Est. completion: Nov 2024383 patients
Phase 1Completed

Evaluate the Pharmacokinetics of BAT2022 in Healthy Chinese Subjects

Start: Jun 2022Est. completion: Nov 202232 patients
Phase 1Completed

To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19.

Start: Apr 2022Est. completion: Nov 202232 patients
Phase 1Completed

A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults

Start: Dec 2021Est. completion: May 202223 patients
Phase 1Completed

To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects

Start: Oct 2021Est. completion: Jan 202224 patients
Phase 1Completed

This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)

Start: Sep 2020Est. completion: Apr 202118 patients
Phase 1Completed

To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects

Start: Jul 2020Est. completion: Nov 202032 patients
Phase 1Completed
NCT05727202Thermo Fisher ScientificThe Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel

Project STARFISH - PRJ0002679

Start: Feb 2023Est. completion: Apr 20241,909 patients
N/ACompleted
NCT05687877AstraZenecaEvusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)

Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)

Start: Jan 2023Est. completion: Jan 2025366 patients
N/ACompleted

A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in Brazil

Start: Jun 2022Est. completion: Jul 2023757 patients
N/ACompleted
NCT05256589Sona NanotechSona Saliva C-19 Rapid Self-test

Clinical Evaluation of the SONA Saliva C-19 Rapid Self-Test for the Detection of COVID-19

Start: Apr 2022Est. completion: May 2022500 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

19 late-stage (Phase 3) programs, potential near-term approvals
30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.